Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652433 | 1.00 | NOTUM (0.46) | NOTUMLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL2875954 | 1.00 | NOTUM (0.46) | NOTUMLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL2878783 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1 | |
| SCHEMBL316646 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1 | |
| SCHEMBL2880648 | 0.86 | ALDH1A1 (0.49) | MAPTALDH1A1 | |
| SCHEMBL28026037 | 0.86 | NOTUM (0.46) | NOTUMLMNAL3MBTL1MAPTRAB9A | |
| SCHEMBL587681 | 0.85 | LMNA (0.53) | LMNAL3MBTL1MAPTRAB9APOLB | |
| Bromide SCHEMBL3964464 | 0.85 | ALDH1A1 (0.47) | MAPTALDH1A1 | |
| SCHEMBL7357706 | 0.85 | ALDH1A1 (0.48) | LMNAPOLBALDH1A1 | |
| SCHEMBL25317162 | 0.82 | LMNA (0.39) | LMNAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023086399-A1 | BIFUNCTIONAL DEGRADERS OF HEMATOPOIETIC PROGENITOR KINASE AND THERAPEUTIC USES THEREOF | NURIX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086341-A1 | INHIBITORS OF KRAS | BIOMEA FUSION, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-8410100-B2 | Pteridinone derivatives as PI3-kinases inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-02 | — | — | US | disclosed |
| EP-2114945-B1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2010-10-20 | — | — | EP | disclosed |
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-22 | — | — | US | disclosed |
| EP-2114945-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008092831-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-07 | — | — | WO | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099680-A1 | PTERIDINONE DERIVATIVES AS P13-KINASES INHIBITORS | PIK3CA, PDPK1, PIK3C3 | NOTUM 3199/4885LMNA 3269/4885L3MBTL1 4578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.